Amylyx Pharmaceuticals, Inc. (AMLX) Stock

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is led by CEO Joshua Cohen, employs 123 people, headquartered in US, publicly traded since 2022.

Amylyx Pharmaceuticals, Inc. (AMLX) stock trades at $27.20 with a market capitalization of $3.41B. The stock is valued at a negative price-to-earnings (P/E) ratio of -19.71, reflecting a net loss over the last twelve months, price-to-book of 12.92, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $10.83 and $41.14, and currently trades 33.9% below its 52-week high.

On profitability, Amylyx Pharmaceuticals, Inc. generates a return on equity (ROE) of -52.92% (negative, reflecting a net loss), return on capital employed of -66.60%.

Amylyx Pharmaceuticals, Inc. by the numbers, 2019–2025

Between 2019 and 2025 Amylyx Pharmaceuticals, Inc. reported revenue of $1.0M rising to $0, a change of -100.0% across 7 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-145.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-151.0M.

Borrowings fell from $15.0M to $6.0M, cash from operations was $-123.0M in the latest year, positive in 1 of the last 7.

Return on equity has averaged -43.8% over five years, and was -47.5% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Amylyx Pharmaceuticals, Inc. (AMLX) — frequently asked questions